Market Overview:
The global drug repurposing market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for novel therapies, and growing focus on personalized medicine. Based on type, the global drug repurposing market is segmented into oncology, CNS diseases, neurodegenerative diseases, and others. Oncology is expected to be the fastest-growing segment during the forecast period owing to increasing incidence of cancer worldwide. Based on application, hospitals are expected to account for the largest share of the global drug repurposing market in 2018 followed by ambulatory surgical centers (ASCs). Geographically, North America is estimated to dominate the global drug repurposing market in 2018 followed by Europe and Asia Pacific.
Product Definition:
Drug repurposing is the use of a drug for a purpose other than that which it was originally intended. Drug repurposing is important because it can help to speed up the process of getting new drugs to market by using drugs that are already approved by the FDA.
Oncology:
Oncology is the study of cancer, a disease of cells. Cancer may start due to mutations or changes in genes and can spread to other organs throught the blood and lymphatic system. The major types of oncology are classified as carcinoma, sarcoma & lymphoma. Cancers that start from malignant neoplasm & proliferating cell may be termed as carcinoma; cancers starting from abnormal cell growth may be termed as sarcoma or lymphoma.
CNS Diseases:
CNS diseases are neurological disorders that result from dysfunction in the Central Nervous System (CNS). The CNS consists of the brain, spinal cord, and nerves. These diseases may affect any part of the CNS but most commonly theyaffect motor and sensory functions. Some common examples include stroke, multiple sclerosis, cerebral palsy, epilepsy as well as movement disorders such as Parkinson’s disease & dystonia.
Application Insights:
Based on the application, the global drug repurposing market is segmented into hospitals, ambulatory surgical centers, others and emergency rooms. The other application segment includes clinics and non-clinical areas of an hospital such as administrative offices. Drug repurposing in ambulatory surgical centers enables healthcare providers to utilize each patient¢â‚¬â„¢s individual history and diagnosis to design a treatment plan that best suits their needs. This has led to an increased number of patients visiting these facilities for follow-up care or new diagnosis related to a previously undiagnosed condition or disease process.
Drugs that are approved by the U.S FDA for use in cancer treatment but cannot be used due to toxicity issues can be safely used for another indication after they have been extensively tested in preclinical trials followed by clinical trials conducted under normal circumstances where there is no evidence of toxic effects (prior TCT).
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to maintain its position throughout the forecast period. This can be attributed to increasing R&D investments by multinational companies, rising healthcare expenditure, growing patient awareness levels coupled with a large base of target population. In addition, Asia Pacific has several emerging countries such as China and India that are making significant progress in terms of research activities along with high unmet clinical needs. These factors are anticipated to boost the demand for drug repurposing in this region over the forecast period.
In addition, Japan’s regulatory authorities have approved two new indications for Exondys 51 (naproxen) which is an old drug having no commercial availability since 2006-07.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases such as heart disease, stroke, cancer, and diabetes accounted for 63% of all deaths in 2012. This number is expected to rise to 73% by 2030. Drug repurposing can help in the treatment of these chronic diseases more effectively and at a lower cost than traditional therapies.
- Advances in genomics and proteomics: The field of genomics has made tremendous strides in recent years with the advent of next-generation sequencing technologies. These technologies have allowed researchers to sequence entire genomes quickly and cheaply. Proteomics is another rapidly growing field that deals with the study of proteins and their interactions within cells. Together, these fields are helping researchers identify new drug targets for various diseases more efficiently than ever before. Drug repurposing can take advantage of this knowledge to develop new therapies for previously untreatable conditions
Scope Of The Report
Report Attributes
Report Details
Report Title
Drug Repurposing Market Research Report
By Type
Oncology, CNS Diseases, Neurodegenerative Diseases, Others
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Astellas Pharma, Biovista, Novartis, AbbVie, Pfizer, Allergan, NuMedii
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Drug Repurposing Market Report Segments:
The global Drug Repurposing market is segmented on the basis of:
Types
Oncology, CNS Diseases, Neurodegenerative Diseases, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- Biovista
- Novartis
- AbbVie
- Pfizer
- Allergan
- NuMedii
Highlights of The Drug Repurposing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oncology
- CNS Diseases
- Neurodegenerative Diseases
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drug Repurposing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Drug repurposing is the process of finding new uses for drugs that have been previously used to treat other diseases or conditions. Drug repurposing can help reduce the cost and wastefulness of drug development, while also improving patient care.
Some of the major companies in the drug repurposing market are Astellas Pharma, Biovista, Novartis, AbbVie, Pfizer, Allergan, NuMedii.
The drug repurposing market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drug Repurposing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drug Repurposing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drug Repurposing Market - Supply Chain
4.5. Global Drug Repurposing Market Forecast
4.5.1. Drug Repurposing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drug Repurposing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drug Repurposing Market Absolute $ Opportunity
5. Global Drug Repurposing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drug Repurposing Market Size and Volume Forecast by Type
5.3.1. Oncology
5.3.2. CNS Diseases
5.3.3. Neurodegenerative Diseases
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drug Repurposing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drug Repurposing Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drug Repurposing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drug Repurposing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drug Repurposing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drug Repurposing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drug Repurposing Demand Share Forecast, 2019-2026
9. North America Drug Repurposing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drug Repurposing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drug Repurposing Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drug Repurposing Market Size and Volume Forecast by Type
9.7.1. Oncology
9.7.2. CNS Diseases
9.7.3. Neurodegenerative Diseases
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drug Repurposing Demand Share Forecast, 2019-2026
10. Latin America Drug Repurposing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drug Repurposing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drug Repurposing Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drug Repurposing Market Size and Volume Forecast by Type
10.7.1. Oncology
10.7.2. CNS Diseases
10.7.3. Neurodegenerative Diseases
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drug Repurposing Demand Share Forecast, 2019-2026
11. Europe Drug Repurposing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drug Repurposing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drug Repurposing Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drug Repurposing Market Size and Volume Forecast by Type
11.7.1. Oncology
11.7.2. CNS Diseases
11.7.3. Neurodegenerative Diseases
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drug Repurposing Demand Share, 2019-2026
12. Asia Pacific Drug Repurposing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drug Repurposing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drug Repurposing Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drug Repurposing Market Size and Volume Forecast by Type
12.7.1. Oncology
12.7.2. CNS Diseases
12.7.3. Neurodegenerative Diseases
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drug Repurposing Demand Share, 2019-2026
13. Middle East & Africa Drug Repurposing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drug Repurposing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drug Repurposing Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drug Repurposing Market Size and Volume Forecast by Type
13.7.1. Oncology
13.7.2. CNS Diseases
13.7.3. Neurodegenerative Diseases
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drug Repurposing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Drug Repurposing Market: Market Share Analysis
14.2. Drug Repurposing Distributors and Customers
14.3. Drug Repurposing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biovista
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AbbVie
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Allergan
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. NuMedii
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
